The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer
The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer: First Prospective Multicentre Observational Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Vit Weinberger, M.D., Ph.D.
- Phone Number: 8306 +42053223
- Email: vit.weinberger@gmail.com
Study Locations
-
-
-
Brno, Czechia, 62500
- Recruiting
- Brno University Hospital
-
Contact:
- Vit Weinberger, M.D., Ph.D.
- Phone Number: 8306 +42053223
- Email: vit.weinberger@gmail.com
-
Contact:
- Jiri Presl, M.D., Ph.D.
- Phone Number: +420377105240
- Email: jiri.presl77@gmail.com
-
Ceske Budejovice, Czechia, 544256
- Recruiting
- Hospital Ceské Budejovice
-
Contact:
- Petr Valha, M.D.
-
Hradec Králové, Czechia
- Recruiting
- Faculty Hospital in Hradec Králové
-
Contact:
- Iva Sedlakova, MD, Ph.D.
-
Jihlava, Czechia
- Recruiting
- Hospital Jihlava
-
Contact:
- Petra Herboltova, MD
-
Pilsen, Czechia, 30100
- Recruiting
- Faculty Hospital Pilsen
-
Contact:
- jiri Presl, M.D., Ph.D.
-
Prague, Czechia, 12000
- Recruiting
- General Hospital Prague
-
Contact:
- Filip Frühauf, M.D.
-
Zlin, Czechia, 585068
- Recruiting
- Regional Hospital Pilsen
-
Contact:
- Pavel Havelka, M.D., Ph.D.
-
-
-
-
-
Debrecen, Hungary
- Recruiting
- University of Derecen
-
Contact:
- Robert Poka, Prof.
-
-
-
-
-
Kielce, Poland, 25734
- Recruiting
- Swietokrzyskie Cancer Center
-
Contact:
- Kamil Zalewski, M.D., Ph.D.
-
Kraków, Poland
- Recruiting
- Cancer Center, M.Sklodowska-Curie Memorial Institute
-
Contact:
- Pavel Blecharz, Prof.
-
Lublin, Poland, 20093
- Recruiting
- Medical University of Lublin
-
Contact:
- Krysztow Kulak, M.D.
-
Szczecin, Poland
- Recruiting
- Pomeranian Medical University
-
Contact:
- Aleksandra Strojna, MD
-
Warsaw, Poland, 02091
- Recruiting
- Medical University of Warsaw
-
Contact:
- Nadil Abdalla, M.D.
-
Wroclaw, Poland, 58413
- Recruiting
- Lower Silesian Cancer Center
-
Contact:
- Marcin Jedryka, M.D., Ph.D.
-
-
-
-
-
Bratislava, Slovakia, 81250
- Recruiting
- Institute of Oncology, Bratislava
-
Contact:
- Ladislav Masak, M.D., Ph.D.
-
Bratislava, Slovakia, 83310
- Recruiting
- National Institute of Oncology, Bratislava
-
Contact:
- Tibor Lengyel, M.D.
-
Bratislava, Slovakia
- Recruiting
- University Hospital Bratislava
-
Contact:
- Mikulas Redecha, MD, Ph.D.
-
Trencin, Slovakia, 505820
- Recruiting
- FN Trencin
-
Contact:
- Peter Kascak, M.D., Ph.D.
-
-
-
-
-
Madrid, Spain, 28046
- Recruiting
- La Paz University Hospital. Madrid
-
Contact:
- Ignacio Zapardiel, M.D., Ph.D.
-
-
-
-
-
L'viv, Ukraine
- Recruiting
- Lviv State Regional Oncological Center
-
Contact:
- Oleh Tsolko, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- advanced ovarian cancer, stage FIGO III and IV
- histology types: high-grade serous, low-grade serous, endometrioid, clear cell, undifferentiated
- completed ovarian cancer surgery and platinum-based chemotherapy
Exclusion Criteria:
- positivity of tumor markers CA 125 and HE4 during study enrollment
- signs of cancer at computed tomography scan during study enrollment
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Advanced ovarian cancer patients
Patient with histologically confirmed advanced (FIGO III and IV) epithelial ovarian, fallopian tube or primary peritoneal carcinoma with complete remission after first line treatment are included into the study.
The patient is regularly followed up every 3-4 months, blood sample collection is performed to determinate tumor marker found in blood, elevated by the presence of cancer recurrence.
In case of one or both of tumor markers are elevated, computed tomography examination with intravenous contrast agent of chest and abdomen is performed to detect the recurrence of the disease.
|
Blood sample collection to determinate tumor marker found in blood elevated by the presence of cancer recurrence.In case of one or both of tumor markers are elevated, computed tomography examination with intravenous contrast agent of chest and abdomen is performed to detect the recurrence of the disease.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum levels of tumor marker CA-125
Time Frame: two years after study enrollment
|
kU/l
|
two years after study enrollment
|
|
Serum levels of tumor marker HE4
Time Frame: two years after study enrollment
|
pmol/l
|
two years after study enrollment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Ovarian cancer recurrence diagnosed by computed tomography scan
Time Frame: two years after study enrollment
|
two years after study enrollment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Vit Weinberger, M.D., Ph.D., University Hospital Brno
- Principal Investigator: Jiri Presl, M.D., Ph.D., University Hospital Pilsen
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HE4
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.